{"title": "Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19 - PubMed", "author": "Username", "url": "https://pubmed.ncbi.nlm.nih.gov/34061355/", "hostname": "ncbi.nlm.nih.gov", "description": "Sepsis induced by bacteria or viruses can result in multiorgan dysfunction, which is a major cause of death in intensive care units. Current treatments are only supportive, and there are no treatments that reverse the pathophysiological effects of sepsis. Vitamin C has antioxidant, anti-inflammatory ...", "sitename": "PubMed", "date": "2021-01-01", "cleaned_text": "Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19 - PMID: 34061355 - PMCID: [PMC8239596](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8239596/) - DOI: [10.1111/bph.15579](https://doi.org/10.1111/bph.15579) Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19 Abstract Sepsis induced by bacteria or viruses can result in multiorgan dysfunction, which is a major cause of death in intensive care units. Current treatments are only supportive, and there are no treatments that reverse the pathophysiological effects of sepsis. Vitamin C has antioxidant, anti-inflammatory, anticoagulant and immune modulatory actions, so it is a rational treatment for sepsis. Here, we summarise data that support the use of megadose vitamin C as a treatment for sepsis and COVID-19. Megadose intravenous sodium ascorbate (150 g per 40 kg over 7 h) dramatically improved the clinical state and cardiovascular, pulmonary, hepatic and renal function and decreased body temperature, in a clinically relevant ovine model of Gram-negative bacteria-induced sepsis. In a critically ill COVID-19 patient, intravenous sodium ascorbate (60 g) restored arterial pressure, improved renal function and increased arterial blood oxygen levels. These findings suggest that megadose vitamin C should be trialled as a treatment for sepsis and COVID-19. British Pharmacological Society. Conflict of interest statement YRL, RB and CNM have a provisional patent on vitamin C use in sepsis (2020901120). Figures Similar articles - [Reversal of the Pathophysiological Responses to Gram-Negative Sepsis by C-An Adjunctive Infection, Sepsis and 7;12(12):3760. doi: 10.3390/nu12123760. Nutrients. 2020. PMID: 33297491 Free PMC article. Review. - [Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial.](/31915072/)Trials. 2020 31915072 Free PMC article. [Evaluation of vitamin C for adjuvant sepsis therapy.](/23682970/)Antioxid Redox Signal. 2013 Dec 10;19(17):2129-40. doi: 23682970 Free PMC article. Review. - [Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized PMC article. Clinical Trial. Cited by - [Association of Vitamin C Treatment with Clinical Outcomes for COVID-19 Patients: A Systematic Review and Meta-Analysis.](/36553979/)Healthcare (Basel). [Dual dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms to Xenobiotic 36184080 Review. - [Intravenous Ascorbic Acid and Lung Function in Severely Ill - Alexander, S. P. H. , Fabbro, D. , Kelly, E. , Mathie, J. A. Veale, , Armstrong, J. F. , Faccenda, , Harding, S. D. , Pawson, A. J. , & Sharman, J. L. (2019a). The concise guide to PHARMACOLOGY 2019/20: Catalytic receptors. British of Pharmacology, 176, S247-S296. 10.1111/bph.14751 - [DOI](https://doi.org/10.1111/bph.14751)- [PMC](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6844576/)- , Kelly, E. , Mathie, J. A. Veale, , Armstrong, J. F. , Faccenda, , Harding, S. D. , Pawson, A. J. , & Sharman, J. L. (2019a). The concise guide to PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 176, S247-S296. 10.1111/bph.14751 - - - Alexander, S. P. H. , Fabbro, D. , Kelly, E. , Mathie, J. A. Veale, , Armstrong, J. F. , Faccenda, , Harding, S. D. , Pawson, A. J. , & Sharman, J. L. (2019b). The concise guide to PHARMACOLOGY 2019/20: Enzymes. British Pharmacology, 176, S297-S396. 10.1111/bph.14752 [PMC](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6844577/)- , Kelly, E. , Mathie, J. A. Veale, , Armstrong, J. F. , Faccenda, , Harding, S. D. , Pawson, A. J. , & Sharman, J. L. (2019b). The concise guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. 10.1111/bph.14752 - - - Alexander, S. P. H. , Kelly, E. , Mathie, A. , Peters, J. A. Veale, , Armstrong, J. F. , Faccenda, Harding, S. , , Sharman, J. L. , & Southan, C. (2019). The concise guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology, 176, S397-S493. 10.1111/bph.14753 [DOI](https://doi.org/10.1111/bph.14753)- [PMC](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6844579/)- [PubMed](/31710713/) , Kelly, , Mathie, A. , Peters, J. A. Veale, , Armstrong, J. F. , Faccenda, Harding, S. , , Sharman, J. L. , & Southan, C. (2019). The concise guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology, 176, S397-S493. C. & Gajdos, P. (1998). Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. British Journal of Clinical Pharmacology, 46, C. & Gajdos, P. (1998). Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. British Journal of Clinical Pharmacology, 46, 589-597. 10.1046/j.1365-2125.1998.00833.x - - Publication types MeSH terms Substances Grant support LinkOut - more resources Full Text Sources Other Literature Sources Medical "}